Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Recruiting 2Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Neoplasms 1500Carcinoma, Non-Small-Cell Lung 1045Prostatic Neoplasms 958Colorectal Neoplasms 882Lung Neoplasms 803Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 541Stomach Neoplasms 513Ovarian Neoplasms 508Neoplasm Metastasis 499Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 356Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Endometrial Neoplasms 305Triple Negative Breast Neoplasms 299Glioblastoma 299Rectal Neoplasms 282Sarcoma 266Urinary Bladder Neoplasms 264Hematologic Neoplasms 264Colonic Neoplasms 255

Interventions

pyrotinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Advanced Breast Cancer × Clear all
NCT07047365 2026-06-03

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
416 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT05856383 2023-05-12

HER2-VIP

Zhejiang Cancer Hospital

Recruiting
100 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡